title: Reply to the Letter to the Editor on "Third generation aromatase inhibitors may prevent endometrial growth and reverse tamoxifen-induced uterine changes in postmenopausal breast cancer patients", by I. Cohen Ann Oncol 2005; 16: 1399.
authors.forename: R
authors.initials: R
authors.lastname: Paridaens
authors.forename: L
authors.initials: L
authors.lastname: Morales
authors.forename: P
authors.initials: P
authors.lastname: Neven
authors.forename: D
authors.initials: D
authors.lastname: Timmerman
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D004717:Endometrium / Q000187:drug effects* / Q000254:growth & development / Q000473:pathology; D005260:Female; D006801:Humans; D017698:Postmenopause; D013629:Tamoxifen / Q000009:adverse effects*; D014591:Uterine Diseases / Q000139:chemically induced* / Q000517:prevention & control*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D013629:Tamoxifen